Evaluation of Macular and choroidal Thickness measurements in HCV patients taking Recent anti viral hepatitis C Drugs (daclatasvir / sofosbuvir) Combination

Abstract Purpose This study aims to evaluate the effect of oral (sofosbuvir / daclatasvir) Combination on macular and choroidal thickness Egyptian patients with chronic hepatitis C virus infection using Optical Coherence Tomography (OCT) Methods was conducted 30 subjects recruited from Viral Hepatitis Treatment Research Centre examined at Ophthalmology Out Patients Clinics, Ain Shams University Hospital during period June 2018 February 2019. All participants underwent full general ocular history taking a precise ophthalmological clinical evaluation including assessment by OCT before starting our Direct Acting Antiviral Drugs (DAAs), sofosbuvir daclatasvir (SOF/ DAC) combination for 12 weeks then, they reassessed again end treatment Spectral Domain optical coherence tomography (SD –OCT) Retina Scan RS - 3000 advance(NIDEK Co., Gamagori Japan) (figure 1). Results Our included 60 eyes no evidence changes have been reported 3 months after onset in all subjects; difference statistically insignificant thickness. Conclusions showed that who were followed showing there best corrected visual acuity (BCVA), observed throughout period.